Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.
Epistemonikos ID: f2c6cf736a49035e1cd188f537e44a44e07f2ecb
First added on: Feb 19, 2024